Acro Biomedical Co., Ltd.
ACBM · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | – | 100% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | 17.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | 2.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | 3% |
| EPS Diluted | -0.002 | -0 | -0 | 0.18 |
| % Growth | -566.7% | -50% | -100.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |